Vitamin D3 for Life

Live Enlightened

Article

Hepatic and Renal Activation of Vitamin D3: Study Summary

Previous related pageHepatic and Renal Activation of Vitamin D3: Full Evidence ReviewNext related pageHow cellular vitamin D metabolism differs between tissues
Study at a glance

Can liver and kidney cells model vitamin D activation in a laboratory device?

Researchers used human liver and kidney cells in connected chambers inside a small laboratory device. Liquid containing vitamin D3 passed through the chambers in sequence. The aim was to model how the liver and kidneys change vitamin D3 into other forms. This was an experiment with cells outside the body, not a study of people receiving treatment.

Which vitamin D form did chemical testing detect?

The liquid leaving the device contained 25-hydroxyvitamin D3, a form made along the way as vitamin D becomes active. This directly confirmed that the device could perform that conversion. Cells grown in the device also showed increased activity of genes for enzymes that process vitamin D compared with cells grown without the flowing system.

How did liquid from the device affect other laboratory cells?

The collected liquid caused changes in genes and proteins linked to cells becoming more mature in a separate laboratory cell test. Most measured responses were stronger when the device included kidney cells than when it contained only liver cells. This supported further processing of vitamin D, but did not identify the final active form directly.

Did the device prove every step of vitamin D activation?

The final active form, 1,25-dihydroxyvitamin D3, was not detected in the liquid. The cell response therefore gives indirect support for further activation, rather than chemical proof of every step. The device does not establish how quickly these processes occur in people, how much each organ contributes or how hormones control them. The separate cell test was not evidence that vitamin D treats cancer or improves other health outcomes.

Read the full article below ↓

This study used interconnected human liver and kidney cell models to investigate whether important stages of vitamin D3 activation could be reconstructed in a microfluidic organ-on-chip system. The researchers directly detected conversion of vitamin D3 to 25-hydroxyvitamin D3 [25(OH)D3] and found that eluate from the connected liver: kidney system produced biological responses consistent with further activation. One qualification is essential: the final active metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] was not itself detected in the chip eluate by LC-MS/MS.

For the complete methodological analysis and evidence boundaries, see Hepatic and Renal Activation of Vitamin D3: Full Evidence Review.

What question did this study investigate?

The researchers wanted to determine whether a connected microfluidic system containing liver and kidney cell models could reproduce sequential stages of vitamin D3 metabolism outside the human body.

The experiment was designed around two linked metabolic territories. HepG2 cells represented hepatic metabolism, while renal proximal tubule epithelial cells represented the renal component. Fluid passing from one chamber to another allowed metabolic products generated upstream to encounter the downstream cell population.

For this evidence slot, the important question is whether the experiment supports the physiological sequence in which vitamin D3 undergoes hepatic and then renal processing.

What was studied?

Study design: Primary in-vitro multi-compartment organ-on-chip experiment.

Population or experimental system: HepG2 liver cells and human renal proximal tubule epithelial cells (RPTEC) grown in connected microfluidic chambers, with HL-60 cells used subsequently as a functional response system.

Exposure or intervention: Vitamin D3-containing medium passed through the microfluidic system.

Primary relevant outcome: Formation of vitamin D3 metabolites and biological activity of the resulting chip eluate.

How was the study carried out?

The researchers cultivated liver and kidney cell models in interconnected microfluidic chambers. Vitamin D3-containing medium was passed through the system, allowing cellular metabolism to occur consecutively as the medium travelled through the chip.

The collected eluate was analysed by LC-MS/MS for vitamin D3 metabolites. The researchers also exposed HL-60 cells to the eluate and measured differentiation-related gene and protein markers. These two approaches served different purposes: chemical analysis asked which metabolites could actually be detected, while the HL-60 experiment asked whether the eluate had biological activity consistent with metabolically activated vitamin D.

What did the researchers find?

The clearest direct finding was formation of 25(OH)D3. LC-MS/MS identified 25(OH)D3 in chip eluate, confirming that supplied vitamin D3 had undergone metabolic hydroxylation within the experimental system.

The researchers also found that expression of CYP2R1, CYP27B1 and CYP24A1 was enhanced under on-chip cultivation compared with static culture conditions. These enzymes are relevant to vitamin D metabolism and supported the metabolic functionality of the microfluidic model.

Eluate from vitamin D3-fed liver: kidney chips produced stronger differentiation-marker responses in HL-60 cells than the relevant control conditions. Comparisons between hepatic-only and liver: kidney configurations also showed stronger induction of most investigated differentiation markers when the renal component was present, supporting an effect of consecutive metabolism.

However, 1,25(OH)2D3 was not detected in the eluate by LC-MS/MS. The functional response was consistent with further vitamin D activation, but it did not constitute direct chemical identification of 1,25(OH)2D3.

What does this study support?

The study supports the proposition that important stages of sequential vitamin D3 metabolism can be reconstructed in a connected liver: kidney cell system. In particular, it provides direct analytical evidence for formation of 25(OH)D3 and functional evidence that adding the renal cellular stage changes the biological activity of the resulting eluate.

For vitamin D activation physiology, this is useful experimental evidence because it treats hepatic and renal metabolism as connected processes rather than isolated reactions.

What does this study not establish?

The study does not directly establish that the complete activation sequence was chemically recovered from the chip. Although 25(OH)D3 was detected, 1,25(OH)2D3 was not detected by LC-MS/MS. Complete activation therefore remains supported indirectly by the functional experiments rather than demonstrated through direct measurement of the final metabolite.

The study also does not establish how quickly these processes occur in an intact person, how strongly different human organs contribute under normal physiological conditions, or how activation is regulated by calcium, phosphate, parathyroid hormone or FGF23.

Finally, the HL-60 experiments should not be interpreted as clinical evidence that vitamin D treats cancer. They were used as a laboratory functional readout of biological activity in the chip eluate, not as a human treatment experiment.

What are the main limitations?

This was an engineered in-vitro model rather than a study of intact human physiology. HepG2 and RPTEC cells reproduce selected cellular characteristics but cannot reproduce the complete architecture, circulation, endocrine regulation and inter-organ communication of living human liver and kidney systems.

The principal evidence limitation is the difference between direct and indirect support for the two activation stages. Formation of 25(OH)D3 was chemically demonstrated. Further activation was supported by functional behaviour of the eluate and by comparisons involving the kidney cell compartment, but 1,25(OH)2D3 itself remained below direct analytical detection in the experiment.

Why this matters within vitamin D physiology

Vitamin D activation is a metabolic sequence. This study experimentally demonstrates why that sequence matters: vitamin D3 entering the system was not simply treated as the final biologically relevant molecule. It was metabolised, 25(OH)D3 was directly identified, and downstream biological activity changed when hepatic and renal cellular components were connected.

The experiment therefore provides a useful model of inter-organ metabolic processing while simultaneously showing why evidence boundaries matter. Demonstrating one metabolite directly and observing biological activity consistent with a later step are not the same form of evidence.

For the broader physiology, see Vitamin D Activation.

For the enzyme pathways involved in vitamin D metabolism, see Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).

For the complete analysis of this study, see Hepatic and Renal Activation of Vitamin D3: Full Evidence Review.

Primary source and publication details

Theobald J, Abu el Maaty MA, Kusterer N, Wetterauer B, Wink M, et al.

In vitro metabolic activation of vitamin D3 by using a multi-compartment microfluidic liver-kidney organ on chip platform.

Scientific Reports. 2019;9:4616.

PMID: 30874583

PMCID: PMC6420623

DOI: 10.1038/s41598-019-40851-9

View the verified primary source

Related reading

Original sources